TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02373410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilicus
Description: Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.~The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lowest rib margin
Description: The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xiphoid
Description: The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nipple
Description: The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilicus Bupivacaine
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lowest rib margin Bupivacaine
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xiphoid Bupivacaine
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nipple Bupivacaine
Description: If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
Study: NCT04526197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 was administered orally as a single dose as 4 x 15 milligram (mg) enteric-coated tablets with 240 milliliters (mL) of water (fasting), for a total dose of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
Study: NCT01058408

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Administered daily 5 days per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered intravenously once a week
Study: NCT00381303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: 600mg bid for 48 wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100mg bid for 48 wks
Study: NCT05213910

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactichoc
Description: dosage form: mix of 8 strains containing 1.2x10\^11 CFU frequency, and duration: 2 capsules/day during 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool sampling
Description: 3 stool samples are taken during the study (D0, D10 and D30)
Study: NCT02877758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomorrowlabs cosmeceutical formulation

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham cosmeceutical formulation
Study: NCT03728374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib ( 12mg, QD, PO, d1-14, 21 days per cycle)
Study: NCT02474160

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Procurement of tissue and blood samples
Study: NCT02737917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Rapid sequence intubation

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Rapid sequence intubation
Study: NCT02513888

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D + diet and lifestyle
Description: subjects will be given vitamin D along with diet and lifestyle modification counselling

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + diet and lifestyle
Description: placebo along with diet and lifestyle modification counselling
Study: NCT03469414

Intervention type: OTHER
Intervention: Craig Handicap Assessment and Reporting Technique
Description: A measure of social participation in individuals with SCI.

Intervention type: OTHER
Intervention: Craig Handicap Assessment and Reporting Technique
Description: A measure of social participation in individuals with SCI.

Intervention type: OTHER
Intervention: PART-O
Description: The PART-O is a community participation measure.

Intervention type: OTHER
Intervention: PART-O
Description: The PART-O is a community participation measure.
Study: NCT03240874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetMama Focus Groups
Description: Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetMama Individual Testing
Description: Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 2 weeks, engage in periodic check-ins with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SweetMama Feasibility Testing - Pilot Randomized Trial
Description: Women will be oriented to SweetMama use on their own Android- or Apple-based phones. The goals of this phase are to collect data from diverse users that will determine acceptability, feasibility, and pilot procedures in anticipation of a fully powered randomized controlled trial. Women will use SweetMama from enrollment (early pregnancy) to up to 8 weeks postpartum, engage in periodic check-ins with the research assistant, and participate in surveys and a semi-structured interview upon completion of SweetMama usage.
Study: NCT01510496

Intervention type: PROCEDURE
Intervention: Inguinal herniorraphy.
Description: Inguinal herniorraphy (non laparoscopic).

Intervention type: PROCEDURE
Intervention: Hysterectomy.
Description: Hysterectomy: Vaginal and abdominal.

Intervention type: PROCEDURE
Intervention: Thoracotomy .
Description: Thoracotomy (non laparoscopic).
Study: NCT05937087

Intervention type: OTHER
Intervention: Community engaged research
Description: The university is working with Navajo communities to conduct an intervention study integrating community based participatory research using an Indigenous research paradigm. The innovative proposed project uses two approaches to build a research partnership to create capacity in the community for community-engaged multilevel behavioral and mental health research. Members from the three Navajo communities have never previously been involved in health research focused on wellbeing. Integrating CBPR with DCSR methodology becomes a powerful innovative intervention as the: 1) the community is driving the research to identify culture-based solutions for health related disparities; 2) the community is provided opportunities through research to center their perspectives and understandings about behavioral and mental health interventions; and 3) the community draws upon their collective community Indigenous knowledge.
Study: NCT00703144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Description: piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic
Study: NCT01604707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Yoga
Description: Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
Study: NCT03376945

Intervention type: DRUG
Intervention: trail cohort
Description: Drug: Omega-3 Fatty Acid-Based Parenteral Nutrition Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid \[FA\] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.

Intervention type: DRUG
Intervention: control cohort
Description: Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Study: NCT00911794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disclosure Writing (Written Disclosure Therapy)
Description: Patients write about a stressful life experience

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neutral (Sham) Writing
Description: Patients write about neutral subjects
Study: NCT03469414

Intervention type: OTHER
Intervention: GPS Tracking
Description: A GPS tracker will be attached to the wheelchairs of a subset of participants for one week. The GPS location is collected every minute, and mapped to Google Maps, which would allow calculation of speed of movement.
Study: NCT00151736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorambucil
Description: Chlorambucil 2mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-etodolac + chlorambucil
Description: R-etodolac 600mg tablets + chlorambucil 2mg tablets
Study: NCT03993860

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Powder
Description: Dry small fish (Chisense) is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sorghum powder
Description: Dry sorghum is roasted and ground into a powder and packed in a sachet (12g) and given to the child at 6 months up to the time the child is 12 moths old. Each month the childs anthropometric measurement are taken to monitor growth.
Study: NCT04050137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: Patients who meet the inclusion criteria and who want to carry out the workshops, fill out an informed consent explaining the procedure to be followed and accepting the cessation of data to carry out the study.~Patients will be divided into 2 working groups (approximately 10 patients in total, in a Gaucher disease group and in another Fabry disease). The workshops will be held at the foundation twice a month in sessions of 45 minutes of work for 3 months (May, June, July 2019). In these sessions the physiotherapists will show the new exercises to the patients. The exercises that are taught in that session should be done at home 3 times a week. In addition, a document will be delivered with the exercises to be carried out and the frequency and intensity of execution. The workshops will be guided at all times by a physiotherapist specialized in therapeutic exercise and EDL.
Study: NCT00913653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Study: NCT02370043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791
Description: Capsules administered orally while fasting, in up to 3 periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KQ-791 (after meal)
Description: Single dose of KQ-791 in capsules, after a meal, in 1 period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, administered orally, in 1 period
Study: NCT03467503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry + soluble fiber
Description: Dietary frozen blueberries and soluble fiber for 20 weeks
Study: NCT03894254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: This is study carried out in current practice. Patients are undergoing a medical examination in a memory center, with extensive and systematic evaluations for the study involving the following tests: IADL, DAD6, New AGGIR, NPI, and mini-Zarit) assessing the functions (autonomy, behavior and caregiver burden).
Study: NCT01313650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 62.5/25mcg
Description: GSK573719/GW64244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 62.5mcg
Description: GSK573719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mcg
Description: GW642444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03093987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical care ultrasound
Description: Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
Study: NCT01749449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and meal frequency
Description: comparison of different levels of protein intake and meal frequency on body composition in obese adults

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and meal frequency
Description: comparison of different levels of protein intake and meal frequency on body composition in obese adults

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and meal frequency
Description: comparison of different levels of protein intake and meal frequency on body composition in obese adults
Study: NCT00026208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 650 mg/m², on week 1 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 650 mg/m², on week 1 and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m², on week 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m², on week 1, 3, 5, 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 5 u/m² intravenously (IV) on week 2, 4, 6, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 5 u/m² intravenously (IV) on week 2, 4, 6, 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy (RT)
Description: 20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.
Study: NCT02084641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over feeding
Description: Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Over feeding
Description: Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
Study: NCT00893646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss counseling
Description: individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
Study: NCT04137900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB004
Description: Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: a human IgG4k monoclonal antibody that specifically binds to the programmed death 1 (PD-1)
Study: NCT00465556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Health Nurse Home Visit
Description: The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intimate Partner Violence (IPV) Protocol
Description: The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
Study: NCT03230656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early cognitive-communication therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early cognitive-communication therapy
Study: NCT00499629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FXR 450
Description: capsule, single oral doses from 10 mg to 450 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule similar to active drug
Study: NCT01244451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
Study: NCT01800422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telapristone acetate
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo surgical resection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03099200

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT04002609

Intervention type: OTHER
Intervention: oxygen
Description: oxygen supplementation during brronchoscopy

Intervention type: OTHER
Intervention: oxygen
Description: oxygen supplementation during brronchoscopy